Is vTv Therapeutics, Inc. overvalued or undervalued?

As of 15 May 2025, the valuation grade for vTv Therapeutics, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial health. The company appears to be overvalued given its current metrics, with a price-to-book value of 6.58 and negative ratios for EV to EBIT and EV to EBITDA at -0.85. Additionally, the return on equity (ROE) is alarmingly low at -291.62%, reflecting severe inefficiencies in generating profit from equity.
In comparison to its peers, vTv Therapeutics shows a stark contrast, with Rezolute, Inc. and SELLAS Life Sciences Group, Inc. also classified as not qualifying, but with less extreme valuations of -4.90 and -5.73 for their respective EV to EBITDA ratios. The industry as a whole is struggling, but vTv's metrics suggest it is particularly vulnerable. Furthermore, the stock has underperformed significantly against the S&P 500 over various time frames, including a 1-year return of -19.38% compared to the index's 10.26%. Overall, vTv Therapeutics is assessed as overvalued in the current market environment.